By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Philips announces exchange ratio for 2025 dividend
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > Philips announces exchange ratio for 2025 dividend
Philips announces exchange ratio for 2025 dividend
Health

Philips announces exchange ratio for 2025 dividend

GlobeNews Wire
Last updated: 02/06/2026 1:40 PM
GlobeNews Wire
Published: 02/06/2026
Share
SHARE

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2025 is 1 new common share for every 26.9341 existing common shares. This ratio was based on the volume-weighted average price of all traded common shares Koninklijke Philips N.V. at Euronext Amsterdam on May 27, 28 and 29, 2026, of EUR 22.8640 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 19,964,655 new common shares.

Shareholders have been given the opportunity to make their choice between a dividend in shares or in cash. The aggregate cash election result was 43.8%.

Delivery of new common shares, with settlement of fractions in cash, if required, and payment of the cash dividend will take place from June 3, 2026, onwards on the basis of share entitlements on the dividend record date. Upon distribution, the total issued share capital will amount to EUR 196,576,957.40, representing 982,884,787 common shares.

More information is available via this link.

For further information, please contact:
Michael Fuchs
Philips Global External Relations
Tel.: +31 6 1486 9261
E-mail: michael.fuchs@philips.com

Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 64,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements and other important information
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Natural Alternatives International, Inc. Announces New Manufacturing Agreement with The Juice Plus+ Company
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis
Surgery Partners, Inc. to Present at Upcoming Investor Conference
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
TAGGED:Amsterdam:NL0000009538NL0000009538NYSE:PHGUS5004723038
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
DAR AL ARKAN PLANS TO LAUNCH “MANHATTAN” MASTERPLAN IN JEDDAH, A LANDMARK DESTINATION ON KING ABDULAZIZ ROAD FEATURING ‘TRUMP PLAZA’
News

DAR AL ARKAN PLANS TO LAUNCH “MANHATTAN” MASTERPLAN IN JEDDAH, A LANDMARK DESTINATION ON KING ABDULAZIZ ROAD FEATURING ‘TRUMP PLAZA’

29/09/2025
IOC Executive Board meeting 9 10 December 2025 Information for the media
Prime Minister Meloni welcomes IOC President and PresidentElect to Palazzo Chigi
Bybit Brings Regulators and Global Payment Leaders Together in Georgia to Explore the Future of Crypto Payments
Acora and Securonix Join Forces to Redefine Security Operations for the AI Era
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?